Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.
about
The Evolution of Advanced Molecular Diagnostics for the Detection and Characterization of Mycoplasma pneumoniaeFirst Report of a Fatal Case Associated with EV-D68 Infection in Hong Kong and Emergence of an Interclade Recombinant in China Revealed by Genome AnalysisRadiologic findings as a determinant and no effect of macrolide resistance on clinical course of Mycoplasma pneumoniae pneumonia.Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children.The spread of Mycoplasma pneumoniae is polyclonal in both an endemic setting in France and in an epidemic setting in Israel.Investigations of Mycoplasma pneumoniae infections in the United States: trends in molecular typing and macrolide resistance from 2006 to 2013.Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang, ChinaAntibiotic sensitivity of 40 Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant isolates from Beijing, China.Molecular Detection and Characterization of Mycoplasma pneumoniae Among Patients Hospitalized With Community-Acquired Pneumonia in the United States.Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010In vitro subminimum inhibitory concentrations of macrolide antibiotics induce macrolide resistance in Mycoplasma pneumoniaeMulticlonal origin of macrolide-resistant Mycoplasma pneumoniae isolates as determined by multilocus variable-number tandem-repeat analysisEpidemiology and clinical features of segmental/lobar pattern Mycoplasma pneumoniae pneumonia: A ten-year retrospective clinical study.Differences in the frequency of 23S rRNA gene mutations in Mycoplasma pneumoniae between children and adults with community-acquired pneumonia: clinical impact of mutations conferring macrolide resistanceSurveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients.Effects of Traditional Chinese Medicine Qinbai Qingfei Concentrated Pellet on Cellular Infectivity of Mycoplasma pneumoniae.Comparison of pyrosequencing, Sanger sequencing, and melting curve analysis for detection of low-frequency macrolide-resistant mycoplasma pneumoniae quasispecies in respiratory specimens.Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients.Macrolide resistance of Mycoplasma pneumoniae, South Korea, 2000-2011Drug resistance mechanisms of Mycoplasma pneumoniae to macrolide antibiotics.Mycoplasma pneumoniae: susceptibility and resistance to antibiotics.Susceptibility of bacterial isolates from community-acquired infections in sub-Saharan Africa and Asia to macrolide antibiotics.Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection.The Value of Macrolide-Based Regimens for Community-Acquired Pneumonia.The role of solithromycin in the management of bacterial community-acquired pneumonia.Resistance to Macrolide Antibiotics in Public Health Pathogens.Epidemiology and Molecular Characteristics of Mycoplasma pneumoniae During an Outbreak of M. pneumoniae-associated Stevens-Johnson Syndrome.Mycoplasma pneumoniae from the Respiratory Tract and Beyond.Clinical Characteristics of Macrolide-Resistant Mycoplasma pneumoniae from Children in Jeju.Characterization of macrolide resistance of Mycoplasma pneumoniae in children in Shenzhen, China.Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients.Prevalence, genotyping and macrolide resistance of Mycoplasma pneumoniae among isolates of patients with respiratory tract infections, Central Slovenia, 2006 to 2014.Nested PCR-linked capillary electrophoresis and single-strand conformation polymorphisms for detection of macrolide-resistant Mycoplasma pneumoniae in Beijing, ChinaGenetic diversity and macrolide resistance of Mycoplasma pneumoniae isolates from two consecutive epidemics in Slovenia.Development of macrolide resistance in Mycoplasma pneumoniae-infected Swedish patients treated with macrolides.Modulation of P1 and EGF expression by Baicalin.High and low doses of clarithromycin treatment are associated with different clinical efficacies and immunomodulatory properties in chronic rhinosinusitis.The timing of azithromycin treatment is not associated with the clinical prognosis of childhood Mycoplasma pneumoniae pneumonia in high macrolide-resistant prevalence settings.Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.
P2860
Q26751077-FF4C9F47-88DF-48E0-8CFF-A3AC0C2C6C50Q33755353-BE6CD088-12C1-497D-B194-188E6097C3BEQ33776351-A1342782-20D9-432A-A957-69CBC22A2957Q34299489-D14B701C-865A-4524-BF68-4C0CA5908239Q34305578-C4EAAE68-4B35-44F6-90DC-05EB28660D44Q34916280-B7F4290E-4559-411D-BD3C-CA2F832BBC2CQ35105923-33B934E6-1BB9-4A80-95EF-692B971A0091Q35689385-753770A7-5A4F-4313-9E0F-472382E2DADCQ35952824-984E394E-1A0E-4927-9D5C-7F08E3B6CBFFQ35980166-A0EA1760-5366-4AE6-8934-3726DB23E3C8Q36071967-40229326-EE4D-4F4D-98BC-6F3D76C0170EQ36171318-867507A8-0E2B-41C3-BE96-6D609D6FAFD6Q36334084-5809A026-33F6-4FB4-82B5-54269A186B22Q36396136-B2EA1DAF-B344-4FBE-ACF9-F523BE0FE48BQ36667124-CC37CE25-FE34-44CD-A895-9673264A39D1Q36785835-ED340B80-8FB0-4FF2-81BF-48178BEFF509Q36978977-E2651269-2A03-4D16-B28A-891B68D8E6E9Q37036304-904F1B49-48F2-4550-95D6-B0122CE24C75Q37036562-30C9D0EB-EACA-44C7-A788-5CB62700D9C1Q37085103-9E07A1C5-1B17-4BB8-8A40-BA9AF1490D27Q37586821-34C169C0-04BF-4F19-8F92-A455FE89175CQ37869911-822CA232-ECC0-45E9-8370-CC2F29EDE900Q37899268-AC93F2BD-2992-494A-B162-B5B599E3C539Q38061407-49E07450-F7DA-4781-A271-E4D5DBD69847Q38601840-9F32CF40-2D50-4057-8689-7E0EB93864ABQ38723961-8341E33C-59A5-40B1-893D-B1B35D5EEBBEQ38928353-E5F0F894-1BCC-429A-BAF9-2B557C171639Q39036185-6B9EFBAE-E509-4E2A-B995-D6D72E173CD4Q39327219-2F5EBEB2-4685-4B93-AB94-5F006338B84CQ40065207-EBE3C477-31CF-418C-B360-300D9A1FF8BCQ40241073-9B701D68-4DAE-413D-85F3-676ACD984D80Q40306177-3407E6BA-A6AE-4D7F-A6FE-6ABA8337526CQ40923171-272BA09B-BB79-493B-901E-43848EFF6949Q41428012-D4A490CF-841D-4D26-8660-07E7973D91F4Q41994190-4749E29A-4087-4E86-B90F-CA8DA3F91D8DQ42232089-3DFC05D3-FCCA-4A5D-AEA4-BF42CBA5A8E1Q43181502-34DDC153-1EEA-45FB-A869-D712F44EA0A7Q48085304-015063CD-8B79-4B72-BBBA-7566124EB5B0Q48149505-A4D98265-B0BA-415E-AE5D-F65E8134CECCQ50047524-47763A7F-6418-4766-A2A6-A0D9DF8CF133
P2860
Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antimicrobial susceptibility o ...... strains from Shanghai, China.
@en
Antimicrobial susceptibility o ...... strains from Shanghai, China.
@nl
type
label
Antimicrobial susceptibility o ...... strains from Shanghai, China.
@en
Antimicrobial susceptibility o ...... strains from Shanghai, China.
@nl
prefLabel
Antimicrobial susceptibility o ...... strains from Shanghai, China.
@en
Antimicrobial susceptibility o ...... strains from Shanghai, China.
@nl
P2093
P2860
P356
P1476
Antimicrobial susceptibility o ...... strains from Shanghai, China.
@en
P2093
P2860
P304
P356
10.1128/AAC.01684-08
P407
P50
P577
2009-03-09T00:00:00Z